| Product Code: ETC7656904 | Publication Date: Sep 2024 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
In 2024, Israel continues to see a steady flow of netupitant palonosetron FDC import shipments, primarily sourced from top exporting countries including Switzerland, UK, Belgium, USA, and Germany. The market remains relatively competitive with a low concentration level, as indicated by the Herfindahl-Hirschman Index (HHI). Despite a slight decline in the compound annual growth rate (CAGR) from 2020 to 2024 at -2.14%, the market appears to have stabilized with a marginal decrease in growth rate from 2023 to 2024 at -0.41%. This suggests a resilient market for netupitant palonosetron FDC in Israel.
| 1 Executive Summary | 
| 2 Introduction | 
| 2.1 Key Highlights of the Report | 
| 2.2 Report Description | 
| 2.3 Market Scope & Segmentation | 
| 2.4 Research Methodology | 
| 2.5 Assumptions | 
| 3 Israel Netupitant Palonosetron FDC Market Overview | 
| 3.1 Israel Country Macro Economic Indicators | 
| 3.2 Israel Netupitant Palonosetron FDC Market Revenues & Volume, 2021 & 2031F | 
| 3.3 Israel Netupitant Palonosetron FDC Market - Industry Life Cycle | 
| 3.4 Israel Netupitant Palonosetron FDC Market - Porter's Five Forces | 
| 3.5 Israel Netupitant Palonosetron FDC Market Revenues & Volume Share, By Type, 2021 & 2031F | 
| 3.6 Israel Netupitant Palonosetron FDC Market Revenues & Volume Share, By Application, 2021 & 2031F | 
| 4 Israel Netupitant Palonosetron FDC Market Dynamics | 
| 4.1 Impact Analysis | 
| 4.2 Market Drivers | 
| 4.2.1 Increasing prevalence of chemotherapy-induced nausea and vomiting (CINV) | 
| 4.2.2 Growing adoption of combination therapies for better management of CINV | 
| 4.2.3 Rising healthcare expenditure and focus on improving patient outcomes | 
| 4.3 Market Restraints | 
| 4.3.1 Stringent regulatory requirements for drug approval | 
| 4.3.2 Limited awareness and accessibility of netupitant palonosetron FDC in Israel | 
| 4.3.3 Presence of alternative treatments for CINV management | 
| 5 Israel Netupitant Palonosetron FDC Market Trends | 
| 6 Israel Netupitant Palonosetron FDC Market, By Types | 
| 6.1 Israel Netupitant Palonosetron FDC Market, By Type | 
| 6.1.1 Overview and Analysis | 
| 6.1.2 Israel Netupitant Palonosetron FDC Market Revenues & Volume, By Type, 2021- 2031F | 
| 6.1.3 Israel Netupitant Palonosetron FDC Market Revenues & Volume, By Flakes, 2021- 2031F | 
| 6.1.4 Israel Netupitant Palonosetron FDC Market Revenues & Volume, By Capsules, 2021- 2031F | 
| 6.1.5 Israel Netupitant Palonosetron FDC Market Revenues & Volume, By Other, 2021- 2031F | 
| 6.2 Israel Netupitant Palonosetron FDC Market, By Application | 
| 6.2.1 Overview and Analysis | 
| 6.2.2 Israel Netupitant Palonosetron FDC Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F | 
| 6.2.3 Israel Netupitant Palonosetron FDC Market Revenues & Volume, By Online Pharmacy, 2021- 2031F | 
| 7 Israel Netupitant Palonosetron FDC Market Import-Export Trade Statistics | 
| 7.1 Israel Netupitant Palonosetron FDC Market Export to Major Countries | 
| 7.2 Israel Netupitant Palonosetron FDC Market Imports from Major Countries | 
| 8 Israel Netupitant Palonosetron FDC Market Key Performance Indicators | 
| 8.1 Number of healthcare facilities offering netupitant palonosetron FDC | 
| 8.2 Patient satisfaction levels with the efficacy of the drug | 
| 8.3 Rate of adoption of combination therapies for CINV management | 
| 9 Israel Netupitant Palonosetron FDC Market - Opportunity Assessment | 
| 9.1 Israel Netupitant Palonosetron FDC Market Opportunity Assessment, By Type, 2021 & 2031F | 
| 9.2 Israel Netupitant Palonosetron FDC Market Opportunity Assessment, By Application, 2021 & 2031F | 
| 10 Israel Netupitant Palonosetron FDC Market - Competitive Landscape | 
| 10.1 Israel Netupitant Palonosetron FDC Market Revenue Share, By Companies, 2024 | 
| 10.2 Israel Netupitant Palonosetron FDC Market Competitive Benchmarking, By Operating and Technical Parameters | 
| 11 Company Profiles | 
| 12 Recommendations | 
| 13 Disclaimer |